‘And Now for Your Entertainment . . . ’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

WASHINGTON-Those were not your ordinary pop bands playing away at the DC Science Writers Association’s annual holiday bash at the National Academy of Sciences building.

WASHINGTON—Those were not your ordinary pop bands playing away at the DC Science Writers Association’s annual holiday bash at the National Academy of Sciences building.

The opening act billed itself as “The Directors.” And, indeed, they were, and all from the National Institutes of Health: Richard D. Klausner, MD, of the National Cancer Institute; Francis S. Collins, MD, PhD, of the National Human Genome Research Institute; and Stephen I. Katz, MD, PhD, of the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

The evening also featured “Wild Type,” a musical ensemble of medical researchers from Johns Hopkins University, led by Bert Vogelstein, MD, professor of oncology. Both bands received a warm reception, but there was general agreement with one guest who suggested to one of the medicomusicians: “Don’t give up your day job.”

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content